Elixir Pharmaceuticals

28 articles with Elixir Pharmaceuticals

• Elixir Pharmaceuticals Signs Option Agreement with a Major Pharmaceutical Company, Novartis Corporation; Deal Could Exceed $500 Million, Completes $12M Equity Financing

  5/20/2009

• Elixir Pharmaceuticals' Phase III Trial of Metformin-Mitiglinide Combination Therapy Demonstrates Significant Reductions in HbA1c (Blood Glucose) Levels Compared to Type 2 Diabetes Patients Not Well-Controlled on Metformin Alone

  11/19/2008

• Elixir Pharmaceuticals to Present at the UBS Warburg Global Life Sciences Conference

  9/18/2008

• Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University School of Medicine

  7/1/2008

• Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation at the Endocrine Society Annual Meeting

  6/18/2008

• Elixir Pharmaceuticals Announces New Data at the 2008 American Diabetes Association Annual Meeting

  6/9/2008

• Elixir Pharmaceuticals Researchers Publish New Data Validating Ghrelin as a Key Metabolic Regulator

  5/28/2008

• Elixir Pharmaceuticals Announces Issuance of SIRT Patent Covering Development of New Therapies Based on Breakthrough Science

  4/28/2008

• Elixir Pharmaceuticals Establishes National Diabetes Advisory Board

  4/9/2008

• Elixir Pharmaceuticals Presents New Data on Ghrelin Inhibition at Keystone Meeting

  2/22/2008

• Elixir Pharmaceuticals to Present at Biotechnology Industry Organization (BIO) CEO & Investor Conference

  2/7/2008

• Elixir Pharmaceuticals Sees IPO of 5 Million Shares at $14-$16 each

  12/18/2007

• Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical Officer

  10/25/2007

• Elixir Pharmaceuticals Plans $86.25 Million IPO

  9/24/2007

• Elixir Pharmaceuticals Initiates Final Phase III Clinical Study Prior to NDA

  8/20/2007

• Elixir Pharmaceuticals to Present Data from Programs to Treat and Prevent Metabolic Diseases

  7/26/2007

• Elixir Pharmaceuticals Announces Presentation of Data in Programs to Treat and Prevent Metabolic Diseases

  7/17/2007

• Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

  6/25/2007

• Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast(R) to Maintain Glycemic Control in Patients with Type 2 Diabetes

  6/25/2007

• Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

  6/5/2007